Over the last 12 months, Revolution Medicines insiders reported no purchases and 10 sales totaling $25.0M across SEC Form 4 filings. 90% of the activity was filed under pre-arranged 10b5-1 trading plans.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Patel SushilD | ▼ Sale | 5,580 | $187.99 | $1.0M | -20.5% | plan · 9 tranches |
| Jun 24, 2026 | Anders JackChief Financial Officer · O | ▼ Sale | 20,000 | $168.33 | $3.4M | -14% | plan · 4 tranches |
| Jun 17, 2026 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 93,575 | $160 | $15.0M | -37.7% | plan · 3 tranches |
| Jun 16, 2026 | Anders JackChief Financial Officer · O | ▼ Sale | 2,722 | $156.12 | $425K | -2.2% | plan |
| Jun 16, 2026 | Kelsey Stephen MichaelSee Remarks · O | ▼ Sale | 4,175 | $156.12 | $652K | -1.4% | plan |
| Jun 16, 2026 | Mancini AnthonySee Remarks · O | ▼ Sale | 4,615 | $156.12 | $720K | -8.5% | — |
| Jun 16, 2026 | GOLDSMITH MARK ASee Remarks · O·D | ▼ Sale | 10,020 | $156.12 | $1.6M | -3.6% | plan |
| Jun 16, 2026 | Cislini JeffGeneral Counsel · O | ▼ Sale | 2,157 | $156.12 | $337K | -3.7% | plan |
| Jun 11, 2026 | Horn Margaret AChief Operating Officer · O | ▼ Sale | 10,000 | $148.01 | $1.5M | -5.9% | plan · 7 tranches |
| May 26, 2026 | Mancini AnthonySee Remarks · O | ▼ Sale | 3,121 | $153.99 | $481K | -5.4% | plan · 3 tranches |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RVMD feed.